转移性割敏感前列腺癌患者的治疗强化实践模式和预测因素
Geoffrey T Gotto1, Steven M Yip2, Bobby Shayegan3
1Southern Alberta Institute of Urology, University of Calgary, Calgary, AB, Canada.
概括
转移性割敏感前列腺癌 (mCSPC) 的治疗强化显著增加. 如今,像阿比拉酸和阿帕胺这样的新型疗法已被广泛使用,这反映了临床试验的进展.
科学领域:
- 在瘤学瘤学.
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 公共卫生 公共卫生
背景情况:
- 抗雄激素剥夺疗法 (ADT) 是转移性割敏感前列腺癌 (mCSPC) 的标准治疗方法.
- 除了ADT之外的治疗强化已经在mCSPC患者中证明了生存益处.
- 需要关于将新型强化疗法整合到mCSPC护理中的真实数据.
研究的目的:
- 评估加拿大阿尔伯塔省 de novo mCSPC 患者治疗强化趋势和预测因素.
- 了解新型药物和化疗如何与ADT一起使用.
- 分析影响采取强化治疗策略的因素.
主要方法:
- 一项以人口为基础的回顾性队列研究,使用电子病历和行政数据.
- 包括在2010年至2020年期间被诊断出新的mCSPC的患者,在ADT上启动.
- 治疗强化定义为在ADT开始后180天内接受特定的新药 (阿帕胺,阿比拉酸,恩扎胺) 或化疗.
主要成果:
- 确定了2515名新的mCSPC患者,2098人开始ADT,525人 (25%) 接受了强化治疗.
- 加剧的速度从3% (2010-2013) 升至67% (2020).
- 在2014年至2017年期间,多西塔克塞尔是普遍存在的,从2018年开始,其后是新型激素药物 (阿比拉酸盐,阿帕胺,恩扎胺). 关键预测因素包括年轻的年龄,较少的并发病,更多的转移部位和最近的诊断年份.
结论:
- 在mCSPC护理中观察到ADT强化疗法的显著增加.
- 采用趋势与临床试验结果和新药批准一致.
- 现实世界的实践反映了晚期前列腺癌治疗的不断变化的格局.
更多相关视频
12:13Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019
6.8K
06:44Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Published on: September 8, 2017
13.3K
相关概念视频
01:21Cancer Survival Analysis
328
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
328
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K